Zanidatamab in HER2-Positive Metastatic Biliary Tract CancerShubham Pant, Omkar Marathe, Hye Jin Choi et al.|JAMA Oncology|2025Cited by 7
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancerJames J. Harding, Jia Fan, Do‐Youn Oh et al.|Future Oncology|2024Cited by 4